NCT01598077 - A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell CarcinomaHER2 + Breast CancerHER2 + Gastric CancerSquamous Cell Carcinoma of Head and NeckEsophageal Squamous Cell Carcinoma

Interventions

DRUG

LJM716

Trial Locations (8)

10002

Novartis Investigative Site, Taipei

60546

University of Chicago Medical Center University of Chicago (16), Chicago

84103

University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City

02114

Massachusetts General Hospital SC-5, Boston

77030-4009

University of Texas/MD Anderson Cancer Center UT MD, Houston

M5G 2M9

Novartis Investigative Site, Toronto

110 744

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona